DDInter1104 DDInter1180
Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States.
Methscopolamine is a quaternary ammonium derivative of scopolamine and antagonist at muscarininc (mACh) receptors. Methscopolamine bromide is the most common form of the active ingredient in oral pharmaceutical products. The oral tablets are used as an adjunct therapy for the treatment of peptic ulcer and is shown to be effective in decreasing the rate of recurrence of peptic ulcers as well as preventing complications.
Lurasidone {u} (Compound) resembles {v} (Compound) Ziprasidone
Lurasidone {u} (Compound) binds {v} (Gene) DRD2
Lurasidone {u} (Compound) causes {v} (Side Effect) Hepatobiliary disease
Lurasidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Lurasidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lanreotide
Lurasidone {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Lurasidone {u} may lead to a major life threatening interaction when taken with {v} Clarithromycin
Lurasidone (Compound) resembles Ziprasidone (Compound)
Lurasidone (Compound) binds DRD2 (Gene)
Lurasidone (Compound) causes Hepatobiliary disease (Side Effect)
Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Lurasidone may lead to a major life threatening interaction when taken with Crizotinib
Lurasidone may lead to a major life threatening interaction when taken with Clarithromycin